Mark Maxfield to Lung Neoplasms
This is a "connection" page, showing publications Mark Maxfield has written about Lung Neoplasms.
Connection Strength
0.910
-
Reddington H, Emmerick I, Diaz Collante J, Maini A, Kanzaria R, Crawford A, Phillips W, Maxfield M, Uy K, Lou F. Survival following sublobar resection after neoadjuvant therapy for T1N1-2M0 lung cancer. PLoS One. 2026; 21(6):e0349231.
Score: 0.149
-
Diaz Collante J, Crawford A, Reddington H, Markel A, Epstein M, Gray C, Lou F, Phillips W, Maxfield M, Uy K, Emmerick I. National trends in lung cancer stage, treatment, and time to treatment initiation after a major healthcare disruption (NCDB 2014-2022). J Cancer Policy. 2026 Jun; 48:100724.
Score: 0.147
-
Reddington H, Ballinger Z, Guart J, Emmerick I, Crawford A, Maxfield M, Uy K, Lou F. National adoption of robotic-assisted thoracoscopic surgery for oncologic lung resections. J Robot Surg. 2025 Sep 04; 19(1):557.
Score: 0.142
-
Reddington H, Emmerick I, Crawford A, Briskin C, Maxfield M, Uy K, Lou F. Safety and Efficacy of Oncologic Second Pulmonary Resections: A Study of The Society of Thoracic Surgeons General Thoracic Surgery Database. Ann Thorac Surg. 2026 02; 121(2):300-309.
Score: 0.139
-
Bai S, Millis M, Wilson S, Scott M, Goulart RA, Maxfield MW, Lou F, Sood RN, Fischer AH. Liquid-based rapid onsite evaluation of endobronchial ultrasound cytologies. J Am Soc Cytopathol. 2022 Nov-Dec; 11(6):375-384.
Score: 0.114
-
Emmerick ICM, Singh A, Powers M, Lou F, Lin P, Maxfield M, Uy K. Factors associated with diagnosis of stages I and II lung cancer: a multivariate analysis. Rev Saude Publica. 2021; 55:112.
Score: 0.110
-
Emmerick ICM, Uy K, Guiab K, Powers M, Lou F, Lin P, Maxfield M, Voland R, Varlotto J. Impact of the National Lung Screening Trial (NLST) publication and Medicare Lung cancer screening payment on lung cancer incidence rates: An interrupted time series analysis. J Cancer Policy. 2022 03; 31:100318.
Score: 0.109